Vol. 4, No. 5 May, 2000
Number |
Subject |
040501 |
Ranbaxy's Ambitious thrust into Europe |
040502 |
Flavopiridol Has Indian Origin |
040503 |
Kopran to Market Perfume Range |
040504 |
Torrent Launches Diabetes Drug |
040505 |
Government Clears Nicholas' ADR Issue |
040506 |
Tax Holiday for Research Has Conditions |
040507 |
Zydus Cadila to Take-over Recon's Formulation Business |
040508 |
JK Pharmachem in Financial Restructuring Exercise |
New Products, Processes & Services
040501 Ranbaxy’s Ambitious thrust into Europe
Ranbaxy is initiating marketing thrust in the European region targetted at 12 European countries comprising: Belgium, Spain, Finland, Sweden, Denmark, Norway, Portugal, Austria, Hungary, Czech Republic and the Slovak Republic. It is in the process of finalising supply contracts for these countries. In Sweden, Finland and Norway its products will be marketed under its own name while in France, it will market to other companies who will sell it under its own name. In UK, Germany and Poland it has its own subsidiaries. The products manufactured in India, will be shipped to its Ireland plant from where it will be distributed across Europe. The company has been working on this strategy for the past 15 years.
040502 Flavopiridol Has Indian Origin
A drug to battle cancer which has its origin in the Hoechst Research Centre at Mulund, Mumbai, reportedly has a 30-40 per cent chance of coming into the market and is useful against multiple forms of cancer, as big as Taxotere. The product has been developed and is in the middle of clinical trials. Hoechst has subsequently merged with Rhone-Poulenc to create Aventis. The drug is reportedly the pride of Aventis’ research and development team. The Hoechst Research Centre at Mulund is where Indian researchers first isolated flavopiridol from a plant source.
040503 Kopran to Market Perfume Range
Kopran Pharma is marketing a range of perfumes called ‘American Dreams.’ It has also entered the gastro-intestinal segment with the digestive table, ‘Yum Tum.’ This will be in Hajmola’s market segment with a market potential of Rs 160 crore. The company has drawn up an ambitious advertising programme for these products.
040504 Torrent Launches Diabetes Drug
A new product Eurepa (repaglinide) suited to Indian type-II diabetic patients has been launched by Torrent Pharmaceuticals. Reportedly the company claims that Eurepa fulfils the long-felt need of endocrinologist, diabetologists, cardiologists, physicians and nephrologist to maintain their patients’ blood sugar levels.
Government Policies
040505 Government Clears Nicholas’ ADR Issue
Among the investment proposals cleared by the government is Nicholas Piramal’s Rs 430-crore ADR proposal. This issue will fund its research and development activities.
040506 Tax Holiday for Research Has Conditions
The finance minister’s move to give a tax holiday to pharmaceutical research and development firms was widely welcomed by the pharmaceutical industry. The condition is that the company will have to be registered in India and will have to complete all necessary formalities between April 1, 2000 and March 31, 2003. Also, their main line of business must be scientific and industrial research and development. Also this tax holiday will be available for a fixed period till March 31, 2013. The WTO regime does not approve of tax holidays but recognises research and development tax exemptions. Since the country will be implementing WTO guidelines this tax holiday will be discontinued after 2013.
Mergers, Acquisitions And Restructuring
040507 Zydus Cadila to Take-over Recon’s Formulation Business
The Rs 478-crore, Zydus Cadila, based in Ahmedabad is in the process of acquiring the formulations business of the Rs 54-crore Recon, based in Bangalore. All the formulation brands of Recon will be transferred to a new joint-venture which will be a subsidiary of Zydus. The acquisition will also include Recon’s export business. The new joint-venture will be called Recon Healthcare with Recon continuing to manufacture formulations at its facilities for the new company. Zydus will hold 90 per cent equity in the company with rest being held by the shareholders of Recon. The acquisition will strengthen Zydus’ formulations business in the analgesic, anti-inflammatory and cardio-vascular segments. Recon’s leading brands are Atenex and Vasonit in the cardio-vascular segment and Inac and Remulide in the pain management segment. They also have the haematinic Ziferrin TR, a sustained release preparation and LANS-OD an anti-ulcerant.
Other News
040508 JK Pharmachem in Financial Restructuring Exercise
JK Pharmachem, the Penicillin-G manufacturer is on a major financial restructuring exercise, which will help it to reduce its debt by 7 per cent. It will convert 25 per cent of its total Rs 90-crore debt into equity. This will enable the company to save Rs 11 crore in costs and is likely help it to post a profit in the next quarter. The approval for the restructuring has been received from financial institutions including UTI and Tidco. UTI and Tidco account for 90 per cent of the total debt. The parent JK Group will also enhance its stake with this exercise.
The company is also undertaking a restructuring in operations. This includes introducing new technology for formulations, new fermentation-based products and stopping power purchases from state electricity boards. It has started manufacturing its own power.
RESULTS INNOVATOR – THE BENCHMARKING TOOL |
||||||||||||||||||
Comp. |
Acc. Year |
Latest Annual Result |
Quarter 1 |
Quarter 2 |
Half Year |
Quarter 3 |
Quarter 4 |
|||||||||||
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
|||||||
Lupin Labs. |
Apr.99 Mar.00 |
715.7 |
25.30 |
190 |
12.86 |
189.3 |
12.8 |
379.4 |
25.66 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
+2.3 |
+30 |
3 |
42 |
3 |
35 |
- |
- |
- |
- |
|||||
Orchid Chem. |
Apr.99 Mar.00 |
359.5 |
38.59 |
- |
- |
- |
- |
175.3 |
19.21 |
- |
- |
- |
- |
|||||
% chng. |
- |
+7.5 |
+8.5 |
- |
- |
- |
- |
+33 |
+9 |
- |
- |
- |
- |
|||||
Pfizer |
Dec.99 Nov.99 |
- |
- |
- |
- |
- |
- |
- |
- |
76.97 |
9.87 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+26 |
+8 |
- |
- |
|||||
Abbott Labs. |
Apr.99 Mar.00 |
- |
- |
- |
- |
58.24 |
2.88 |
- |
- |
28.04 |
1.19 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+8 |
+73 |
- |
- |
+18 |
+85 |
- |
- |
|||||
Pun. Chem. |
Apr.99 Mar.00 |
- |
- |
- |
- |
19.18 |
0.09 |
37.67 |
.19 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
-13 |
-91 |
-5 |
-90 |
- |
- |
- |
- |
|||||
Unichem Labs. |
Apr.99 Mar.00 |
- |
- |
- |
- |
56.38 |
4.88 |
- |
- |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+8 |
+35 |
- |
- |
- |
- |
- |
- |
|||||
Ranbaxy Labs. |
Apr.99 Mar.00 |
- |
- |
- |
- |
409.7 |
77.9 |
- |
- |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
-1.6 |
+54 |
- |
- |
- |
- |
- |
- |
|||||
Glaxo |
Jan.99 Dec.00 |
- |
- |
- |
- |
- |
- |
- |
- |
248 |
16 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+32 |
-26 |
- |
- |
|||||
Shashun Chem. |
Apr.99 Mar.00 |
165.7 |
7.50 |
- |
- |
42.89 |
4.55 |
- |
- |
48.60 |
6.38 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
-1 |
+82 |
- |
- |
+18 |
+234 |
- |
- |
|||||
Suven Pharma. |
Apr. 99 Mar.00 |
30.98 |
2.50 |
- |
- |
9.73 |
1.02 |
- |
- |
9.45 |
1.14 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+13 |
+54 |
- |
- |
+9 |
+65 |
- |
- |
|||||
Neuland Labs. |
Apr.99 Mar.00 |
65.97 |
2.1 |
- |
- |
18.51 |
n.a. |
- |
- |
19.89 |
.43 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+8 |
n.a. |
- |
- |
+29 |
+38 |
- |
- |
|||||
Cipla |
Apr.99 Mar.00 |
617.2 |
114.9 |
- |
- |
199.7 |
35.75 |
- |
- |
187.1 |
34.82 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+23 |
+14 |
- |
- |
+14 |
+5 |
- |
- |
|||||
Panacea Biotec |
Apr.99 Mar.00 |
- |
- |
- |
- |
- |
3.66 |
57.95 |
5.70 |
85.40 |
11.94 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
+35 |
+39 |
+36 |
+107 |
+234 |
- |
- |
|||||
Torrent Pharma. |
Apr.99 Mar.00 |
- |
- |
- |
- |
101.1 |
18.80 |
- |
- |
161.2 |
22.9 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+13 |
+75 |
- |
- |
+103 |
+229 |
- |
- |
|||||
Knoll Pharma |
Jan.99 Dec.99 |
- |
- |
- |
- |
- |
- |
- |
- |
77.5 |
40.6 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+9 |
+286 |
- |
- |
|||||
Parke Davis |
Apr.99 Mar.00 |
200.3 |
16.61 |
- |
- |
52.93 |
4.31 |
101.0 |
8.14 |
51.08 |
6.78 |
- |
- |
|||||
% chng. |
- |
+11 |
+139 |
- |
- |
+6 |
+85 |
+0.2 |
+42 |
+7 |
+276 |
- |
- |
|||||
Makers Labs |
Apr.99 Mar.00 |
23.95 |
0.80 |
- |
- |
8.93 |
0.3 |
17.05 |
0.64 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+20 |
+11 |
+17 |
+42 |
- |
- |
- |
- |
|||||
Sun Pharma |
Apr.99 Mar.00 |
335.6 |
59.04 |
- |
- |
112.8 |
22.79 |
215.8 |
42.8 |
112.3 |
22.89 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+35 |
+53 |
+41 |
+60 |
+24 |
+48 |
- |
- |
|||||
Bal Pharma |
Apr.99 Mar.00 |
24.89 |
0.62 |
- |
- |
8.26 |
0.44 |
14.44 |
0.57 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+22 |
+158 |
+17 |
+72 |
- |
- |
- |
- |
|||||
Vorin Labs |
Apr.99 Mar.00 |
72.85 |
2.35 |
- |
- |
15.56 |
0.19 |
35.1 |
12.5 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
-43 |
-76 |
-20 |
-42 |
- |
- |
- |
- |
|||||
Ipca Labs |
Apr.99 Mar.00 |
335.4 |
21.4 |
- |
- |
95.22 |
8.09 |
171.8 |
15.9 |
96.58 |
6.76 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+1 |
+105 |
+0.5 |
+48 |
+20 |
+60 |
- |
- |
|||||
Dr. Reddy’s |
Apr.99 Mar.00 |
- |
- |
- |
- |
113.5 |
- |
239.9 |
- |
121 |
22 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+4 |
- |
+7 |
- |
+34 |
+103 |
- |
- |
Comp. |
Acc. Year |
Latest Annual Result |
Quarter 1 |
Quarter 2 |
Half Year |
Quarter 3 |
Quarter 4 |
|||||||||||
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
Sales (Cr.) |
Net (Cr.) |
|||||||
J B Chem. |
Apr.’99 Mar.’00 |
152.8 |
14.53 |
- |
- |
40.65 |
4.65 |
82.78 |
10.15 |
43.60 |
5.54 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+3 |
+75 |
+5 |
+30 |
+27 |
+121 |
- |
- |
|||||
Dabur India |
Apr.’99 Mar.’00 |
914.7 |
51.60 |
- |
- |
261.6 |
18.91 |
495.1 |
440.1 |
286.4 |
15.41 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+6 |
-21 |
+12 |
+91 |
+10 |
+15 |
- |
- |
|||||
Morepen Labs. |
Apr.’99 Mar.’00 |
256.5 |
34.3 |
- |
- |
84.6 |
12.2 |
155.5 |
21.6 |
84.7 |
12.4 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+24 |
+43 |
+28 |
+43 |
+30 |
+42 |
- |
- |
|||||
Nich. Piramal |
Apr.’99 Mar.’00 |
- |
- |
- |
- |
124.2 |
14.12 |
237.1 |
25.57 |
114.6 |
11.23 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+12 |
+25 |
+12 |
+23 |
+11 |
+22 |
- |
- |
|||||
Wock- hardt. |
Jul.’98 Dec.’99 |
- |
- |
209.0 |
34.0 |
- |
- |
- |
- |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
+36 |
+45 |
- |
- |
- |
- |
- |
- |
- |
- |
|||||
Ind-Swift Labs |
Apr.’99 Mar.’00 |
42.65 |
12.3 |
- |
15.58 |
.8 |
29.85 |
1.55 |
16.08 |
.85 |
- |
- |
||||||
% chng. |
- |
- |
- |
- |
- |
+54 |
+220 |
+58 |
+288 |
+76 |
+205 |
- |
- |
|||||
Veronica Labs. |
Apr.’99 Mar.’00 |
7.19 |
.25 |
- |
- |
5.81 |
.41 |
11.08 |
.92 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||
Auro- bindo |
Apr.’99 Mar.’00 |
550.0 |
50.14 |
- |
- |
174.2 |
18.61 |
357.3 |
37.2 |
178 |
19.57 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+20 |
+63 |
+44 |
+85 |
+31 |
+35 |
- |
- |
|||||
Novartis India |
Apr.’99 Mar.’00 |
- |
- |
- |
- |
- |
- |
424 |
49 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||
FDC |
Apr.’99 Mar.’00 |
140.2 |
15.28 |
- |
- |
- |
- |
- |
- |
28.02 |
4.86 |
- |
- |
|||||
% chng. |
- |
- |
-2 |
+19 |
- |
- |
||||||||||||
Glenmark |
Apr.’99 Mar.’00 |
138.0 |
21.96 |
- |
- |
- |
- |
- |
- |
30.15 |
4.90 |
- |
- |
|||||
% chng. |
- |
+39 |
+71 |
- |
- |
- |
- |
- |
- |
+6 |
+191 |
- |
- |
|||||
Aarti |
Apr.’99 Mar.’00 |
132.3 |
4.05 |
- |
- |
- |
- |
- |
- |
32.13 |
1.55 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
-5 |
+86 |
- |
- |
|||||
Duphar |
Apr.’99 Mar.’00 |
64.49 |
3.82 |
- |
- |
- |
- |
- |
- |
19.55 |
2.61 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+27 |
+15 |
- |
- |
|||||
Kopran |
Apr.’99 Mar.’00 |
203.7 |
10.30 |
- |
- |
- |
- |
- |
- |
56.75 |
4.01 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+10 |
-7 |
- |
- |
|||||
Siris |
Apr.’99 Mar.’00 |
240.8 |
10.09 |
- |
- |
- |
- |
- |
- |
31.94 |
-20.4 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
-35 |
- |
- |
- |
|||||
Krebs Bio |
Apr.’99 Mar.’00 |
36.84 |
11.27 |
- |
- |
- |
- |
- |
- |
12.23 |
3.92 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+52 |
+30 |
- |
- |
|||||
Jenburkt |
Apr.’99 Mar.’00 |
13.93 |
.25 |
- |
- |
- |
- |
- |
- |
3.92 |
.17 |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+27 |
+9 |
- |
- |
|||||
Max India |
Jul.’99 Jun.’00 |
288 |
176 |
- |
- |
41.03 |
12.29 |
77.32 |
22.76 |
- |
- |
- |
- |
|||||
% chng. |
- |
- |
- |
- |
- |
+68 |
+403 |
+50 |
+340 |
- |
- |
- |
- |